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OBJECTIVE— The purpose of this study was to examine the relationship of glycemic control
and exogenous and endogenous insulin levels with all-cause and cause-specific mortality (isch-
emic heart disease and stroke) in an older-onset diabetic population.
RESEARCH DESIGN ANDMETHODS— The Wisconsin Epidemiologic Study of Di-
abetic Retinopathy (WESDR) is an ongoing, prospective, population-based cohort study of
individuals with diabetes first examined in 1980–1982. A stratified sample of all individuals with
diabetes diagnosed at 30 years of age or older was labeled “older-onset” (n  1,370). Those
participating in the 1984–1986 examination phase (n  1,007) were included in the analysis.
Endogenous insulin was determined by measurements of plasma C-peptide (in nanomoles per
liter), and exogenous insulin was calculated in units per kilogram per day. Glycemic control was
determined by levels of glycosylated hemoglobin (HbA1).
RESULTS— After 16 years of follow-up, 824 individuals died (all-cause mortality); 358
deaths involved ischemic heart disease and 137 involved stroke. C-peptide and HbA1 were
significantly associated with all-cause and ischemic heart disease mortality in our study. The
hazard ratio (95% CI) values for all-cause mortality were 1.12 (1.07–1.17) per 1% increase in
HbA1, 1.20 (0.85–1.69) per 1 unit  kg
1  day1 increase in exogenous insulin, and 1.15
(1.04–1.29) per 1 nmol/l increase in C-peptide and for ischemic heart disease mortality were
1.14 (1.06–1.22), 1.50 (0.92–2.46), and 1.19 (1.02–1.39) for HbA1, exogenous insulin, and
C-peptide, respectively, after adjusting for relevant confounders. C-peptide was associated with
stroke mortality only among men (1.65 [1.07–2.53]).
CONCLUSIONS— Our results show that individuals with higher endogenous insulin levels
are at higher risk of all-cause, ischemic heart disease, and stroke mortality.
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There has been an interest in investi-gating the association of high levelsof endogenous and exogenous insu-
lin with cardiovascular morbidity and
mortality (1–9), particularly after the
results of the Diabetes Control and
Complications Trial (DCCT), which
recommended tight glycemic control in
order to decrease the risk of microvascu-
lar complications in diabetic individuals
(10). The rationale has been based on re-
sults from clinical and experimental stud-
ies that demonstrated the influence of
exogenous insulin on arterial wall
changes that ultimately contributed to the
development of atherosclerosis (11–13).
However, increased levels of endogenous
insulin and the use of exogenous insulin
have been associated with increased car-
diovascular morbidity and mortality in
some studies (3,5–7,9) but not in others
(2,14,15). The purpose of this study was
to investigate the relationship of glycemic
control and exogenous and endogenous
insulin levels with all-cause and cause-
specific mortality (ischemic heart disease
and stroke) in an older-onset diabetic
population.
RESEARCH DESIGN AND
METHODS— The Wisconsin Epide-
miologic Study of Diabetic Retinopathy
(WESDR) is an ongoing, prospective,
population-based cohort study of indi-
viduals who were receiving care for dia-
betes in 11 counties in Wisconsin in
1978–1979. A stratified sample of all in-
dividuals with diabetes diagnosed at 30
years of age or older was included and was
labeled “older-onset” (n  1,370). The
first examination phase was in 1980 –
1982, and follow-up examinations were
performed every 4–6 years. Plasma C-
peptide was first measured at the 1984–
1986 follow-up visit, which, for the
purposes of this report, was considered to
be the baseline examination (n 1,007).
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Detailed protocols used in WESDR
have been published elsewhere (16,17).
Briefly, baseline and all follow-up exami-
nations included detailed medical history
with information about cardiovascular
disease (CVD) and cigarette smoking and
measurements of blood pressure, height,
and weight. Nonfasting endogenous insu-
lin was determined by measurement of
plasma C-peptide (in nanomoles per li-
ter), and exogenous insulin was calcu-
lated in units per kilogram per day.
Glycemic control was determined by lev-
els of glycosylated hemoglobin (HbA1).
Stereoscopic seven-field 30o color retinal
photographs were taken, and diabetic ret-
inopathy was classified according to a
modified Airlie House Classification
Scheme (18).
Deaths were ascertained by contact-
ing family members and physicians, re-
view of newspaper obituaries, and use of
vital status records. For cause-specific
analyses, any mention on the death certif-
icate was considered an event. Causes of
death were defined according to the ICD
9th and 10th revisions. Ischemic heart
disease mortality was defined according
to codes 410.0 – 414.9 (ICD-9) and
I20.0–I25.9 (ICD-10), and stroke mortal-
ity was defined according to codes
430.0–438.9 (ICD-9) and I60.0–I69.9
(ICD-10). The survival interval consid-
ered in the current analysis was a 16-year
period from baseline until death or the
date of last contact by 31 December 2002.
Of the 1,007 examined, 824 had died,
151 were living as of 31 December 2002,
and 32 had their last living contact date
before 31 December 2002. The survival
interval for the latter group was the period
between the baseline examination and the
last contact date.
Diabetic retinopathy was defined as the
presence of mild (i.e., microaneurysms
only, hard or soft exudates, or hemor-
rhages with or without microaneurysms)
or worse retinopathy. A positive history of
CVD was defined as having history of an-
gina, heart attack, or stroke. A person was
considered hypertensive if systolic or di-
astolic blood pressure was 140 or 90
mmHg, respectively, or using antihyper-
tensive medication. Current smokers
were those who had smoked more than
100 cigarettes and continued to smoke
until the day of the examination.
Statistical analysis
Age- and sex-adjusted and multivariable
analyses were performed. The use of ex-
ogenous insulin was analyzed as a binary
variable (yes/no) and as a continuous vari-
able (units  kg1  day1), and plasma
C-peptide (nmol/l) and HbA1 (%) were
analyzed as continuous variables in the
whole population. To analyze the influ-
ence of the use of exogenous insulin on
mortality, we calculated a propensity
score that was a conditional probability of
receiving insulin given some individual
covariates (age, duration of diabetes, lev-
els of HbA1, BMI, history of CVD, and
presence of diabetic retinopathy) in order
to decrease the chances of bias by indica-
tion (i.e., physicians tend to prescribe in-
sulin to those with poorer glycemic
control and therefore at higher risk for
developing comorbidities and for death).
Propensity score was then added to our
regression models, and multivariable
analyses were performed with the Cox
proportional hazards model. Hazard ra-
tios (HRs) and 95% CIs were estimated,
and P values 0.05 were considered
significant.
In addition, HbA1, plasma C-peptide,
and exogenous insulin were categorized
into tertiles or quartiles. Dummy vari-
ables were created and added into multi-
variable models. It was observed that the
magnitude of HRs remained constant for
each category increment in all these vari-
ables. For example, C-peptide was cate-
gorized into tertiles, and changes from
one tertile to another showed similar HR
values (1.05); thus, those variables
were kept as a continuous variable in our
analyses. Analyses were performed using
SAS version 9 (SAS Institute, Cary, NC).
The institutional review board ap-
proved the study, and consent forms were
obtained from all participants. This re-
search was conducted in accordance
with the principles of the Declaration of
Helsinki.
RESULTS— After 16 years of follow-
up, 824 individuals died (all-cause mor-
tality); 358 deaths involved ischemic
heart disease, and 137 involved stroke.
Table 1 shows the characteristics of indi-
viduals with older-onset diabetes at base-
line. The mean age was 68.6 11.0 years,
and 44.9% of the individuals were male.
Age- and sex-adjusted HR showed
that HbA1 was significantly associated
with increased all-cause (HR 1.13 [95%
CI 1.09–1.17], per 1% increase) and isch-
emic heart disease mortality (1.14 [1.08–
1.21], per 1% increase) (Table 2). Use of
exogenous insulin was also associated
with increased age- and sex-adjusted
all-cause mortality (1.62 [1.41–1.87]
comparing those using vs. not using ex-
ogenous insulin and 1.70 [1.23–2.34]
per 1 unit  kg1  day1 increase) and
ischemic heart disease mortality (1.74
[1.40 –2.16] comparing those using vs.
not using exogenous insulin and 2.10
[1.32–3.36] per 1 per 1 unit  kg1 
day1 increase). Plasma C-peptide was
not significantly associated with all-
cause mortality (0.95 [0.87–1.03] per 1
nmol/l increase) and ischemic heart dis-
ease mortality (0.96 [0.85–1.09] per 1
nmol/l increase) in the age- and sex-
adjusted models.
In multivariable analyses, HbA1 and
C-peptide were significantly associated
with all-cause and ischemic heart disease
mortality after controlling for potential
confounders (age, sex, BMI, duration of
diabetes, systolic blood pressure, history
Table 1—Baseline characteristics of individuals with older-onset diabetes in the 1984–1986
WESDR
n
Mean  SD
or %
Age (years) 1,007 68.6  11.0
Duration of diabetes (years) 1,007 15.3  7.9
HbA1 (%) 980 9.3  1.9
C-peptide (nmol/l) 960 1.0  0.9
Systolic blood pressure (mmHg) 979 143.1  23.3
Diastolic blood pressure (mmHg) 978 75.4  12.3
BMI (kg/m2) 884 29.1  5.9
Sex (percent male) 1,006 44.9
Insulin use (yes) 1,007 56.4
Cardiovascular disease (present) 990 34.1
Hypertension (present) 991 57.0
Smoking status (current) 1,001 12.9
Diabetic retinopathy (present) 992 66.0
Insulin, cardiovascular disease, and diabetes
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of CVD, diabetic retinopathy status, and
smoking) (Table 2). We also assessed the
association of HbA1, plasma C-peptide,
and amount of insulin used with mortal-
ity stratified by sex in our multivariable
analysis. HbA1 was associated with in-
creased all-cause mortality among both
men (HR 1.16 [95% CI 1.08–1.25]) and
women (1.09 [1.03–1.15] per 1% in-
crease), with ischemic heart disease mor-
tality among both men (1.24 [1.11–
1.38]) and women (1.09 [1.00–1.19]),
and with stroke mortality among men
only (1.26 [1.10–1.53]). Higher levels of
plasma C-peptide were also associated
with increased all-cause mortality among
women (1.18 [1.03–1.36] per 1 nmol/l
increase) and ischemic heart disease mor-
tality (1.43 [1.13–1.83]) and stroke mor-
tality (1.65 [1.07–2.53]) among men
(Table 3).
Analysis of a subsample (n  369)
showed that the inclusion of serum lipids
in our multivariable models did not
change the positive association of endog-
enous insulin (HR 1.12 [95% CI 0.96–
1.32] for all-cause and 1.09 [0.87–1.38]
for ischemic heart disease) or exogenous
insulin (1.17 [0.87–1.57] for all-cause
and 1.18 [0.75–1.84] for ischemic heart
disease mortality).
CONCLUSIONS— The WESDR
provides a unique opportunity to investi-
gate long-term longitudinal associations
of risk factors due to its population-based
design and length of follow-up. Our re-
sults showed that higher levels of endog-
enous insulin, measured by plasma levels
of C-peptide at baseline, and HbA1 were
associated with increased risk of all-cause
and CVD mortality among individuals
with older-onset diabetes.
In our study, exogenous insulin was
associated with all-cause and ischemic
heart disease mortality independently of
HbA1 level. Our results are consistent
with data from previous population-
based studies investigating the associa-
tion of endogenous insulin and mortality
(6,7,19). However, most of these studies
were done in the general population. In a
population-based study in Finland, hy-
perinsulinemia had a modest association
with increased cardiovascular mortality
in middle-aged men (7). In a meta-
analysis, Hu et al. (6) evaluated 11 Euro-
pean studies and concluded that plasma
fasting insulin levels were associated with
a 1.5-times increased chance of CVD
mortality in men and 2.7 in women af-
ter controlling for potential confounders.
In the Atherosclerosis Risk in Com-
munities (ARIC) study, higher levels of
endogenous insulin were significantly as-
sociated with increased thickness of the
carotid artery wall in both men and
women (20). It is believed that insulin
stimulates smooth muscle cell prolifera-
tion in arterial walls and increases lipid
synthesis and, as a consequence, leads to
the formation of lipid lesions in arterial
tissues (12). Insulin is also associated with
the activation of plasminogen activator
inhibitor-1, which is involved in the de-
velopment of thrombosis (21).
In our study, higher levels of plasma
C-peptide were also associated with in-
creased risk of death involving stroke
among men. In the ARIC study (22), ele-
vated fasting insulin concentrations were
also associated with up to a 19% increase
in ischemic stroke incidence.
We found positive relationships be-
tween exogenous insulin use and mortal-
ity in our age- and sex-adjusted models.
However, the use of exogenous insulin
could have been targeted more to those at
higher risk of developing complications
and possibly with higher risk of death.
Thus, the significant associations ob-
served in the age- and sex-adjusted mod-
els were no longer statistically significant
after the adjustment for several confound-
ers and the propensity score. Although
some studies showed positive associa-
tions between the use of exogenous insu-
lin and the development of CVD, findings
from randomized controlled clinical trials
showed that the benefits of tight glycemic
control in reducing the risk of long-term
complications of diabetes (i.e., retinopa-
thy, nephropathy, and neuropathy) out-
weigh the possible harmful effects of
exogenous insulin treatment (13,23). The
University Group Diabetes Program
showed no evidence that insulin treat-
ment influenced the risk of CVD or mor-
tality (24) in individuals with type 2
diabetes. The Epidemiology of Diabetes
Interventions and Complications (EDIC)
study, a long-term follow-up of the
DCCT, reported a slower rate of progres-
sion of arterial wall thickness (25) and a
42% reduced risk of cardiovascular
events (26) in the intensive therapy group
compared with the group under conven-
tional treatment among type 1 diabetic
patients. In the UK Prospective Diabetes
Study (UKPDS), there was no increase in
rates of myocardial infarction among par-
ticipants assigned to receive either insulin
therapy or sulfonylurea compared with
those under conventional therapy (diet)
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(27). However, hyperglycemia was asso-
ciated with increased risk of myocardial
infarction in that study (28), providing
further evidence of the benefits of tight
glycemic control.
One of the major concerns regarding
the role of endogenous or exogenous in-
sulin as a predictor of CVD has been their
close association with other important
risk factors for CVD such as obesity,
dyslipidemia, and hypertension (29).
Despre´s et al. (19) reported that hyper-
insulinemia was an independent risk fac-
tor for incident ischemic heart disease in
the Quebec Cardiovascular Study, after
controlling for these variables. In our
study, adjustments for potential con-
founders, as well as the role of glycemic
control, were addressed in our multivari-
able analysis. However, residual con-
founding is always a concern. We did not
adjust for levels of serum lipids in our
analysis because serum levels of choles-
terol and HDL were only measured in a
subsample of this cohort (n  369) dur-
ing this second examination phase. Anal-
ysis of this subsample showed that the
inclusion of lipid profile in our multivari-
able models did not change the positive
association between endogenous or exog-
enous with all-cause and ischemic heart
disease mortality. These associations were
not statistically significant possibly due to
the smaller sample size. In addition, the
need to have insulin therapy and the
higher levels of endogenous insulin might
reflect underlying insulin resistance,
which is also known to be associated with
some CVD risk factors such as atheroscle-
rosis, dyslipidemia, and hypertension
(8,30).
Another possible limitation might be
due to loss to follow-up in the 4-year in-
terval between the between the first and
second examination phases. Because we
used the second follow-up visit as base-
line, if death (our main cause of loss to
follow-up) was associated with insulin
levels or use of exogenous insulin, we
might have underestimated the strength
of the association reported. In addition,
women had a lower number of events
(i.e., deaths) than men, and therefore low
power might have also influenced our
ability to detect associations among fe-
male participants.
Future reports from clinical trials
such as the Bypass Angioplasty Revascu-
larization Investigation 2 Diabetes (BARI
2D) Trial (31), with longer follow-up, may
lead to a better understanding of the influ-
ence of insulin in cardiovascular morbid-
ity and mortality. Our results support the
idea that individuals with higher endoge-
nous insulin levels should be closely fol-
lowed due to their higher risk of all-cause
and ischemic heart disease mortality.
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